What does this research mean for the field?

The engineered multiarmed nanovesicle tPA@CTG provides targeted, thrombin-responsive delivery of tissue plasminogen activator, achieving near-complete recanalization and significantly reduced bleeding risk compared to free tPA in a rat thrombosis model. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To engineer and evaluate a multiarmed nanovesicle platform for targeted, thrombin-triggered delivery of tissue plasminogen activator with integrated MRI monitoring.

August 22, 2026Advanced Healthcare Materials

Thrombin‐Responsive Multiarmed Nanovesicles for Targeted Delivery of Tissue Plasminogen Activator and MRI‐Monitored Thrombolysis

View Full Paper

Ask AI

Bookmark

Authors

YHYu HuangDonghua University JZJinlong ZhangShanghai Sixth People's Hospital XYXuehao YuYunnan Normal University

Discussion

Member takes

Implication

Animal study demonstrates targeted nanovesicles achieve near-complete recanalization in rat thrombosis models, suggesting effective clot dissolution with reduced bleeding risk.

Key Points

To engineer and evaluate a multiarmed nanovesicle platform for targeted, thrombin-triggered delivery of tissue plasminogen activator with integrated MRI monitoring.
Designed tPA@CTG nanovesicles combining CREKA-mediated clot targeting, thrombin-responsive payload release, and MRI contrast capabilities.
Tested clot binding and activation under static and flow conditions, followed by therapeutic evaluation in a rat carotid artery thrombosis model.
Analyzed microenvironment changes through transcriptomic profiling and evaluated systemic biocompatibility and hemorrhage risk.
tPA@CTG achieved a thrombolytic efficiency of 99.5 ± 0.6% and blood flow recovery of 95.1 ± 2.5% in rats, outperforming free tPA even at half the dose.
Transcriptomic profiling revealed active modulation of complement and coagulation pathways within the thrombotic microenvironment.
Nanovesicle administration demonstrated high biocompatibility and significantly lower bleeding risk compared to free tPA.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/6a898131ca7ade938187f35d https://doi.org/10.1002/adhm.71632

View Full Paper

Ask AI

Bookmark

Implication

Animal study demonstrates targeted nanovesicles achieve near-complete recanalization in rat thrombosis models, suggesting effective clot dissolution with reduced bleeding risk.

Thrombin‐Responsive Multiarmed Nanovesicles for Targeted Delivery of Tissue Plasminogen Activator and MRI‐Monitored Thrombolysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Thrombin‐Responsive Multiarmed Nanovesicles for Targeted Delivery of Tissue Plasminogen Activator and MRI‐Monitored Thrombolysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider